Published in Clin Dev Immunol on August 16, 2011
Role of toll-like receptor 4 on lupus lung injury and atherosclerosis in LPS-challenge ApoE⁻/⁻ mice. Clin Dev Immunol (2013) 0.82
Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus. Arthritis Res Ther (2016) 0.79
Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Mediators Inflamm (2014) 0.79
Possible evidence of systemic lupus erythematosus and periodontal disease association mediated by Toll-like receptors 2 and 4. Clin Exp Immunol (2015) 0.78
Expression of TLR-7, MyD88, NF-kB, and INF-α in B Lymphocytes of Mayan Women with Systemic Lupus Erythematosus in Mexico. Front Immunol (2016) 0.76
Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. J Immunol (2013) 0.75
Expression of Toll‑like receptors 3 and 9 in Egyptian systemic lupus erythematosus patients. Z Rheumatol (2016) 0.75
Relevant genetic polymorphisms and kidney expression of TLR5 and TLR9 in lupus nephritis. Clin Exp Immunol (2017) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J Exp Med (1985) 4.16
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum (2004) 2.03
Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol (2001) 1.95
Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med (2010) 1.83
Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol (2003) 1.79
Death, autoantigen modifications, and tolerance. Arthritis Res (2000) 1.75
Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol (2007) 1.68
TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol (2007) 1.56
Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol (2011) 1.49
TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol (2006) 1.44
Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer (2003) 1.40
Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum (2007) 1.37
Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun (2006) 1.29
Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev (2010) 1.24
The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol (2006) 1.16
Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine (2010) 1.15
Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells. J Immunol (2009) 1.14
Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J Exp Med (2008) 1.10
Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther (2007) 1.07
Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum (2010) 1.02
Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol (2008) 0.98
Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol (2011) 0.96
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
Differential development of plasmacytoid dendritic cells in Th1- and Th2-like cytokine milieus. Allergy (2010) 0.91
Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome. Arthritis Rheum (2007) 0.89
Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. J Autoimmun (2010) 0.86
DcR3/TR6 modulates immune cell interactions. J Cell Biochem (2003) 0.83
Tuning inflammation in tuberculosis: the role of decoy receptors. Microbes Infect (2009) 0.78
Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol (2010) 3.71
Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01
Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood (2011) 2.20
Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med (2003) 1.86
Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol (2009) 1.76
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 1.73
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 1.65
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum (2003) 1.62
Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci (2013) 1.50
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum (2009) 1.41
Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol (2013) 1.37
Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res (2010) 1.36
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology (2010) 1.36
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One (2009) 1.33
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29
Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol (2006) 1.26
Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol (2007) 1.24
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 1.20
Characterization of lung gamma delta T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guérin. J Immunol (2003) 1.19
CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J Immunol (2006) 1.19
Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis (2011) 1.18
Gamma delta T cells inhibit in vitro growth of the asexual blood stages of Plasmodium falciparum by a granule exocytosis-dependent cytotoxic pathway that requires granulysin. Eur J Immunol (2004) 1.17
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther (2008) 1.12
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11
Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J Exp Med (2008) 1.10
Psoriatic Arthritis. N Engl J Med (2017) 1.09
Reciprocal stimulation of gammadelta T cells and dendritic cells during the anti-mycobacterial immune response. Eur J Immunol (2004) 1.09
Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. J Leukoc Biol (2006) 1.08
Identification of epitopes of Mycobacterium tuberculosis 16-kDa protein recognized by human leukocyte antigen-A*0201 CD8(+) T lymphocytes. J Infect Dis (2002) 1.08
Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol (2006) 1.08
Mechanisms underlying lineage commitment and plasticity of human γδ T cells. Cell Mol Immunol (2012) 1.07
Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum (2011) 1.07
Selective depression of interferon-gamma and granulysin production with increase of proliferative response by Vgamma9/Vdelta2 T cells in children with tuberculosis. J Infect Dis (2002) 1.07
Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol (2005) 1.06
New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis (2009) 1.05
Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol (2005) 1.04
Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol (2007) 1.04
γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol (2011) 1.03
New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol (2006) 1.01
An anti-inflammatory role for V alpha 14 NK T cells in Mycobacterium bovis bacillus Calmette-Guérin-infected mice. J Immunol (2003) 1.00
Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol (2008) 1.00
Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS One (2012) 0.99
Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells. J Immunol (2010) 0.99
NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum (2005) 0.95
Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock. J Leukoc Biol (2006) 0.94
IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren's syndrome and is associated with the local expansion of pro-inflammatory CD14(bright)CD16+ monocytes. Rheumatology (Oxford) (2013) 0.94
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther (2013) 0.93
IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol (2007) 0.93
IL-21 regulates the differentiation of a human γδ T cell subset equipped with B cell helper activity. PLoS One (2012) 0.93
Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy. Tuberculosis (Edinb) (2007) 0.93
Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis. J Immunol (2010) 0.93
IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann Rheum Dis (2012) 0.93
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. Tuberculosis (Edinb) (2008) 0.92
gammadelta T cells condition dendritic cells in vivo for priming pulmonary CD8 T cell responses against Mycobacterium tuberculosis. Eur J Immunol (2006) 0.91
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem (2008) 0.90
Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis. Arthritis Rheum (2004) 0.89
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int (2009) 0.89
Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. Cancer Res (2009) 0.88
Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity. PLoS One (2013) 0.88
Colorectal cancer stem cells and cell death. Cancers (Basel) (2011) 0.87
A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçet's disease. Clin Exp Rheumatol (2010) 0.86
Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. Arthritis Res Ther (2003) 0.86
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatol Int (2009) 0.86
Vascular endothelial growth factor gene polymorphisms in Behçet's disease. J Rheumatol (2004) 0.86
Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg Med Chem Lett (2006) 0.85
Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum (2010) 0.85
CD133 as a target for colon cancer. Expert Opin Ther Targets (2012) 0.85
Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis (2012) 0.84
Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Anticancer Agents Med Chem (2009) 0.84
Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis. Rheumatology (Oxford) (2013) 0.84
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. Expert Rev Clin Immunol (2013) 0.84
Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A (2012) 0.84
Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. Rheumatol Int (2009) 0.84
Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer. Curr Med Chem (2008) 0.83
Homing and memory patterns of human gammadelta T cells in physiopathological situations. Microbes Infect (2005) 0.83
Th0 to Th1 switch of CD4 T cell clones specific from the 16-kDa antigen of Mycobacterium tuberculosis after successful therapy: lack of involvement of epitope repertoire and HLA-DR. Immunol Lett (2004) 0.82
Gammadelta T cell modulation in anticancer treatment. Curr Cancer Drug Targets (2010) 0.82